Replies to post #312066 on Elite Pharmaceuticals Inc (ELTP)

[dr_lowenstein]

There is no such literature

really???

https://www.ncbi.nlm.nih.gov/pubmed/28592699


Send to
J Neurosci. 2017 Jul 12;37(28):6761-6777. doi: 10.1523/JNEUROSCI.2946-16.2017. Epub 2017 Jun 7.
Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease.
Ortner NJ1, Bock G1, Dougalis A2, Kharitonova M1, Duda J2, Hess S3, Tuluc P1, Pomberger T1, Stefanova N4, Pitterl F5, Ciossek T6, Oberacher H5, Draheim HJ6, Kloppenburg P3, Liss B2, Striessnig J7.


However, in our study isradipine plasma concentrations approved for therapy were not neuroprotective in a PD mouse model. We provide an explanation for this observation by demonstrating that during SN DA-like neuronal activity LTCCs are less sensitive to isradipine than Cav1.2 LTCCs in resistance blood vessels (mediating dose-limiting vasodilating effects) and even at supratherapeutic concentrations isradipine fails to reduce somatic Ca2+ oscillations of SN DA neurons.


Sorry LOL LOL